NMDA receptor pathways as drug targets

Top Cited Papers

28 October 2002

journal article
review article
Published by Springer Nature in Nature Neuroscience

Vol. 5 (S11) , 1039-1042
https://doi.org/10.1038/nn936

Abstract

Since the mid 1980s, there has been a great deal of enthusiasm within both academia and industry about the therapeutic potential of drugs targeting the NMDA subtype of glutamate receptors. That early promise is just beginning to translate into approvable drugs. Here we review the reasons for this slow progress and critically assess the future prospects for drugs that act on NMDA receptor pathways, including potential treatments for some major disorders such as stroke and Alzheimer's disease, for which effective therapies are still lacking.

Keywords

This publication has 29 references indexed in Scilit:

Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits
Nature, 2002
Pharmacological Characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a Novel Subtype-Selective N-Methyl-d-Aspartate Antagonist
The Journal of Pharmacology and Experimental Therapeutics, 2002
NMDA receptor antagonists as analgesics: focus on the NR2B subtype
Published by Elsevier ,2001
NMDA receptors as targets for drug action in neuropathic pain
European Journal of Pharmacology, 2001
Glycine Antagonist in Neuroprotection for Patients With Acute Stroke
JAMA, 2001
Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial
The Lancet, 2000
Glycine-site antagonists and stroke
Expert Opinion on Investigational Drugs, 1999
Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn
Neuropharmacology, 1999
Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A
Nature, 1998
N-methyl-D-aspartic acid receptor structure and function
Physiological Reviews, 1994